Discovery of benzimidazole-diamide finger loop (Thumb Pocket I) allosteric inhibitors of HCV NS5B polymerase: Implementing parallel synthesis for rapid linker optimization

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 1, 2010, Pages 196-200

  Goulet, Sylvie ^a   Poupart, Marc André ^a   Gillard, James ^a   Poirier, Martin ^a   Kukolj, George ^a   Beaulieu, Pierre L ^a  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

Allosteric inhibitors; HCV; Hepatitis C virus; Inhibition; NS5B polymerase; Replication; Replicon

Indexed keywords

2 FUROIC ACID; 4 BENZOIC AMIDE DERIVATIVE; 5 HYDROXYTRYPTOPHAN DERIVATIVE; AMIDE; AMINOCINNAMIC ACID DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; BENZOFURAN DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; CINNAMIC ACID; DIAMIDE; INDOLE DERIVATIVE; NONSTRUCTURAL PROTEIN 5B; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIPOPHILICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION;

ALLOSTERIC REGULATION; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CINNAMATES; DIAMIDE; DRUG DISCOVERY; ENZYME INHIBITORS; HUMANS; MICROSOMES, LIVER; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 72049106897     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.10.136     Document Type: Article

References (20)

1. Choo Q.-L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., and Houghton M. Science 244 (1989) 359
2. Lavanchy D. Liver Int. 29 (2009) 74
3. Farnik H., Mihm U., and Zeuzem S. Liver Int. 29 (2009) 23
4. For reviews on NS5B polymerase inhibitors, see:. Beaulieu P.L. Expert Opin. Ther. Pat. 19 (2009) 145 and references cited therein
5. For a review on inhibition of other HCV targets see, for example:. De Francesco R., and Migliaccio G. Nature 436 (2005) 953
6. Manns M.P., Foster G.R., Rockstroh J.K., Zeuzem S., Zoulim F., and Houghton M. Nat. Rev. Drug Disc. 6 (2007) 991
7. McKercher G., Beaulieu P.L., Lamarre D., LaPlante S., Lefebvre S., Pellerin C., Thauvette L., and Kukolj G. Nucleic Acids Res. 32 (2004) 422
8. Beaulieu P.L. Curr. Opin. Drug Discovery Dev. 9 (2006) 618
9. Beaulieu P.L., Bös M., Bousquet Y., Fazal G., Gauthier J., Gillard J., Goulet S., LaPlante S., Poupart M.-A., Lefebvre S., McKercher G., Pellerin C., Austel V., and Kukolj G. Bioorg. Med. Chem. Lett. 14 (2004) 119
10. Beaulieu P.L., Bös M., Bousquet Y., DeRoy P., Fazal G., Gauthier J., Gillard J., Goulet S., McKercher G., Poupart M.-A., Valois S., and Kukolj G. Bioorg. Med. Chem. Lett. 14 (2004) 967
11. Beaulieu P.L., Bousquet Y., Gauthier J., Gillard J., Marquis M., McKercher G., Pellerin C., Valois S., and Kukolj G. J. Med. Chem. 47 (2004) 6884
12. Harper S., Pacini B., Avolio S., Di Filippo M., Migliaccio G., Laufer R., De Francesco R., Rowley M., and Narjes F. J. Med. Chem. 48 (2005) 1314
13. Ontoria J.M., Martin Hernando J.I., Malancona S., Attenni B., Stansfield I., Conte I., Ercolani C., Habermann J., Ponzi S., Di Filippo M., Koch U., Rowley M., and Narjes F. Bioorg. Med. Chem. Lett. 16 (2006) 4026
14. Beaulieu P.L., Gillard J., Bykowski D., Brochu C., Dansereau N., Duceppe J.-S., Haché B., Jakalian A., Lagacé L., LaPlante S., McKercher G., Moreau E., Perreault S., Stammers T., Thauvette L., Warrington J., and Kukolj G. Bioorg. Med. Chem. Lett. 16 (2006) 4987
15. Leeson P.D., and Springthorpe B. Nat. Rev. Drug Disc. 6 (2007) 881
16. Gleeson M.P. J. Med. Chem. 51 (2008) 817
17. Kalgutkar A.S., Gardner I., Obach R.S., Shaffer C.L., Callegari E., Henne K.R., Mutlib A.E., Dalvie D.K., Lee J.S., Nakai Y., O'Donnell J.P., Boer J., and Harriman S.P. Curr. Drug Metab. 6 (2005) 161
18. LaPlante S., Jakalian A., Aubry N., Bousquet Y., Ferland J.-M., Gillard J., Lefebvre S., Poirier M., Tsantrizos Y., Kukolj G., and Beaulieu P.L. Angew. Chem., Int. Ed. 43 (2004) 4406
19. 50 values were determined as described in Ref. 6 and are the average of at least two independent determinations unless indicated otherwise.
20. 50 determinations in the cell-based replicon assay were performed in duplicates using RT-PCR for RNA quantification as described in: Beaulieu, P. L.; Fazal, G.; Goulet, S.; Kukolj, G.; Poirier, M.; Tsantrizos, Y.; Jolicoeur, E.; Gillard, J.; Poupart, M.-A.; Rancourt, J. WO Patent WO 03/010141, 2003. Total replicon RNA levels were normalized to control cellular GAPDH mRNA. Compounds were devoid of cytotoxicity at inhibitory concentrations. For an overview and basic protocols on the use of HCV replicons, see Lohmann, V. Meth. Mol. Biol. 2009, 510, 145: Hepatitis C: Methods and Protocols, 2nd ed.; Tang, H., Ed.; Humana Press.